Hemp&Health Signs Agreement to Grow Medical Cannabis in Poland

Hemp&Health SA has officially signed an agreement to start growing medical cannabis in Poland. As reported by Money.pl, the agreement was concluded with a research institute supervised by the Minister of Agriculture and Rural Development. This is a key step, because according to the Act on Counteracting Drug Addiction of July 29th, 2005, only authorized institutions can cultivate medical cannabis in Poland.

This cooperation opens up new possibilities in the field of research and production of domestic medical cannabis. Importantly, the cultivation will be carried out in strictly controlled indoor conditions, in accordance with GACP (Good Agricultural and Collection Practice) standards. Thanks to this, the quality of the raw material will be high, and the process itself will meet pharmaceutical requirements.

Medical cannabis cultivation details from Hemp&Health

Hemp&Health will provide the research institute with modern infrastructure that meets rigorous cultivation standards. The cultivation process will take place in several stages:

Stage one: annual production of 136 kg of dried medical cannabis.

Stage two: expansion of infrastructure, which will ultimately allow for the cultivation of up to 800 kg per year.

The project will be implemented using a container farm purchased in September 2024, as well as a 1,400 m² industrial building. Both facilities are located on a 0.5 ha property, which provides adequate space for further expansion.

Raw material processing and distribution

All harvested hemp plants containing THC above 0.3% will be processed into pharmaceutical raw material. The subsidiary THC Factory sp. z o. o. , which has the necessary technological facilities, will be responsible for this process.

What does this mean for patients?

Stability of supply – Polish medical cannabis is not subject to import limits, which reduces the risk of shortages in pharmacies.

Local production = greater quality control – patients can count on high standards of cultivation and processing.

Shortening the supply chain – medical cannabis will reach Polish pharmacies faster than in the case of import.

THC Pharma SA, a company belonging to the Hemp&Health capital group, will be responsible for the distribution of the final product . This means that H&H will cover the entire process – from cultivation, through processing, to delivery of the raw material to pharmacies.

It is worth noting that locally grown cannabis is not subject to import restrictions. In 2025, the limit for medical cannabis import to Poland is 20 tons, which often causes shortages in pharmacies. Thanks to domestic production, patients will have more stable access to the drug, without having to wait for deliveries from abroad.

Action Plan for 2025: In the coming months, Hemp&Health will focus on achieving two key goals:

Investment in infrastructure – it is necessary to adapt the facilities to the rigorous requirements of the GACP standard, which will ensure high quality of production.

Obtaining a permit – The research institute must obtain the consent of the Chief Pharmaceutical Inspector to conduct cultivation, which is necessary for the legal functioning of the project.

Benefits for patients and the pharmaceutical market

Starting local production of medical cannabis is a huge step forward for patients in Poland. If GIF grants permission to start cultivation, it will:

The availability of cannabis in pharmacies will increase, which will reduce the problem of shortages and interruptions in therapy.

Prices could become more competitive as dependence on foreign suppliers decreases.
Quality control will be more transparent because the entire process – from cultivation to distribution – will take place in Poland.

In addition, Hemp&Health will create a business model that will allow for margins at every stage of the supply chain. This could mean financial stability for the company and further development of the medical cannabis market in Poland.

The signed agreement is a milestone in the development of the Polish medical cannabis market. Local cultivation, processing of the raw material and distribution by a Polish company is not only a chance to increase the availability of the drug for patients, but also the possibility of independence from imports.

__

(Featured image by Roberto Valdivia via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in FaktyKonopne. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us